Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11148284 | 0.87 | ACHE (0.42) | TAAR1MAPTMEN1KMT2AACHE | |
| SCHEMBL2954181 | 0.84 | TAAR1 (0.56) | TAAR1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL8269049 | 0.78 | TAAR1 (0.52) | TAAR1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL3677762 | 0.78 | TAAR1 (0.52) | TAAR1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL10718639 | 0.78 | CYP3A4 (0.33) | ALDH1A1 | |
| SCHEMBL12330214 | 0.75 | TAAR1 (0.48) | TAAR1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL14507701 | 0.74 | TAAR1 (0.48) | TAAR1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL12326171 | 0.74 | TAAR1 (0.48) | TAAR1MAPTSMN1; SMN2MEN1KMT2A | |
| Ethylamine SCHEMBL6314624 | 0.72 | TAAR1 (0.63) | TAAR1MAPTSMN1; SMN2MEN1KMT2A | |
| Acetonitrile SCHEMBL6315753 | 0.72 | TAAR1 (0.47) | TAAR1MAPTSMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014764-A1 | N-myristoyltransferase inhibitor compositions and methods of use | SMITH CHARLES D (US) | 2004-01-22 | — | — | US | claimed |
| US-20040014764-A1 | N-myristoyltransferase inhibitor compositions and methods of use | SMITH CHARLES D (US) | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014764-A1 | N-myristoyltransferase inhibitor compositions and methods of use | NMT2, NMT1, MBOAT1 | TAAR1 4563/4885MAPT 133/4885SMN1; SMN2 3958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.